AcelRx to Host Fourth Quarter and Full Year 2020 Financial Results Call and Webcast on March 15, 2021

Rhea-AI Summary

AcelRx Pharmaceuticals announced it will release its fourth quarter financial results after market close on March 15, 2021. A conference call and webcast will be held at 4:30 p.m. ET to discuss these results. Investors can join the call by dialing specific numbers based on their location. AcelRx focuses on innovative therapies for pain management, with one approved product in the U.S., DSUVIA, and another in development, Zalviso. More details can be found on their website.

Positive

• AcelRx has one approved product in the U.S., DSUVIA, for acute pain management.
• Zalviso is in development as a patient-controlled analgesia system.
• Both DSUVIA and Zalviso are approved products in Europe.

Negative

• None.

REDWOOD CITY, Calif., March 8, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter financial results after market close on Monday, March 15, 2021. AcelRx management will host a live webcast and conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on March 15, 2021 to discuss the financial results and provide an update on the company's business.

The webcast is accessible by visiting the Investors page of the company's website at www.acelrx.com and clicking on the webcast link on the Investors home page. The webcast will be accompanied by a slide presentation.  A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor page of the company's website at www.acelrx.com.

Investors who wish to participate in the conference call may do so by dialing (866) 361-2335 for domestic callers, (855) 669-9657 for Canadian callers, or (412) 902-4204 for international callers.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA®(sufentanil sublingual tablet, 30 mcg), known as DZUVEO™ in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso®(sufentanil sublingual tablet system, SST system, 15 mcg), being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is an investigational drug and not approved in the U.S. For additional information about AcelRx, please visit www.acelrx.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-to-host-fourth-quarter-and-full-year-2020-financial-results-call-and-webcast-on-march-15-2021-301242642.html

SOURCE AcelRx Pharmaceuticals, Inc.

FAQ

When is AcelRx’s fourth quarter financial results call scheduled?

AcelRx’s fourth quarter financial results call is scheduled for March 15, 2021, at 4:30 p.m. ET.

How can I access the AcelRx financial results webcast?

The AcelRx financial results webcast can be accessed on the company's Investors page at www.acelrx.com.

What is AcelRx's ticker symbol?

AcelRx's ticker symbol is ACRX.

What products does AcelRx have approved in the U.S.?

AcelRx has one approved product in the U.S., DSUVIA, which is used for managing acute pain.

What is the purpose of the Zalviso product candidate?

Zalviso is being developed as a patient-controlled analgesia system for moderate-to-severe acute pain.